Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (3325)	6/21/1999 4:58:00 PM
From: Don Miller	Respond to of 10280

Sorry, Two Points Were Intermingled. point 1. June 10 BancBoston downgrade based upon JNJ withdrawal from marketing Nori. See the quote at the bottom of my previous post. Then today JNJ withdraws Hismanal. This to me is a statement of both strength about Nori, and concern for risk of Hismanal liability. BancBoston downgraded June 10 using JNJ's combined marketing withdrawal as justification. What we really have is actually a hard retreat by JNJ, in the face of a better drug. point 2. Will we see other racemic drugs withdrawn from the market as the increased risk is proven in studies of the optically pure isomer. BB Lawyer's question. Is there increased product liability for the racemic producer when the racimec bad consequences have been at least prevented or possibly definitively proven in the pure isomer studies? Sorry there was a chain of logic there for me somewhere.